Skip to main content
. 2013 Nov;3(11):130130. doi: 10.1098/rsob.130130

Figure 3.

Figure 3.

AROS is redundant for survival in non-cancer cell lines. (a) Phase contrast micrographs 72 h following targeting of AROS or SIRT1 in ARPE19, WI-38 and MCF10A non-cancer cells. (b) Western blotting for AROS protein following RNAi in each cell line. β-Actin is used as a loading control. (c) Quantification of apoptotic induction following targeting of SIRT1 and AROS in non-cancer cells. Apoptosis following mock transfection is set to 1.0.